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Abstract
Background: MicroRNAs (miRNAs) are 21~25-nucleotides (nt) long and interact with mRNAs
to trigger either translational repression or RNA cleavage through RNA interference (RNAi),
depending on the degree of complementarity with the target mRNAs. Our recent study has shown
that HIV-1 nef dsRNA from AIDS patients who are long-term non-progressors (LTNPs) inhibited
the transcription of HIV-1.
Results:  Here, we show the possibility that nef-derived miRNAs are produced in HIV-1
persistently infected cells. Furthermore, nef short hairpin RNA (shRNA) that corresponded to a
predicted  nef  miRNA (~25 nt, miR-N367) can block HIV-1 Nef expression in vitro and the
suppression by shRNA/miR-N367 would be related with low viremia in an LTNP (15-2-2). In the
15-2-2 model mice, the weight loss, which may be rendered by nef was also inhibited by shRNA/
miR-N367 corresponding to suppression of nef expression in vivo.
Conclusions: These data suggest that nef/U3 miRNAs produced in HIV-1-infected cells may
suppress both Nef function and HIV-1 virulence through the RNAi pathway.
Background
The human immunodeficiency virus (HIV), which infect
humans cause acquired immunodeficiency syndrome
(AIDS), which has reached pandemic levels in some soci-
eties, especially those in Southern Africa and Southeast
Asia [1]. Given the immensity of HIV pandemic, the
development of a rather safe and cheap, effective thera-
peutics, has become the main focus [2]. Several strategies
attempted to control the spread of AIDS have not shown
major breakthrough and the vaccines have shown little
promise as far as their efficacy is concerned. However, one
approach used extensively in other diploid organisms,
which now has tremendous potential to encourage antivi-
ral defense against HIV appears to be double stranded
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RNA-dependent post-transcriptional gene silencing or
RNA interference (RNAi).
RNAi is a defense mechanism against aberrant transcripts
that may be produced during viral infection and mobili-
zation of transposons [3,4]. The RNAi pathway has been
implicated in silencing transposons in the C. elegans germ-
line [5,6], silencing stellate repeats in the Drosophila germ-
line, and the response against invading viruses in plants
[7]. Post-transcriptional regulation by RNAi is mediated
by small non-coding RNAs (~25-nucleotides; nt). Small
interfering RNAs (siRNAs) are short RNA duplexes that
direct the degradation of homologous transcripts [8]. In
contrast, the single stranded microRNAs (miRNAs) bind
to 3' untranslated regions of mRNA with complementarity
of 50 to 85% to give translational repression without tar-
get degradation [9]. The mature miRNA (~25-nt) is pro-
duced by processing of ~70-nt precursor stem-loop
hairpin RNAs (Pre-miRNA) by Dicer [10,11]. At the
moment several human diseases, including spinal muscu-
lar atrophy (Paushkin et al., 2002), fragile X mental retar-
dation [13,14] and chronic lymphocytic leukemia [15]
have been identified as illnesses in which miRNAs or their
machinery might be implicated. However, up until now
there has been no clear-cut scientific proof that establishes
the exact correlation between miRNAs and human infec-
tious diseases such as AIDS.
One of the human immunodeficiency virus type 1 (HIV-
1) coding accessory genes, nef, is located at the 3' end of
the viral genome and partially overlaps the 3'-long termi-
nal repeat (LTR). The nef gene is uniquely conserved in
HIV-1, HIV-2 and simian immunodeficiency virus (SIV)
and is not essential but important for viral replication in
vivo [16]. The nef gene is expressed during HIV infection
and often accounts for up to 80% of HIV-1 specific RNA
transcripts during the early stages of viral replication [2].
Our own investigations have shown that defective vari-
ants of nef dsRNA containing the 3'-LTR regions, obtained
from long-term non-progressor (LTNP) AIDS patients,
actually inhibited the transcription of HIV-1 [17]. Further-
more, cis-expression of mutated F12-HIV-1 nef inhibits
replication of highly productive NL43-HIV-1 strain,
which is not related to down-regulation of CD4 [18,19].
It has been demonstrated that F12 nef gene cloned from
the provirus of naturally occurring HUT-78 T cells infected
with the supernatant of the peripheral blood mononu-
clear cells (PBMCs) of an HIV-seropositive non-producer
patient, induces a block of viral replication [19]. Thus, it
has been suggested that nef RNAs may be a cis-regulatory
factor for HIV-1 replication [20].
In the current study, we have established the link between
miRNAs and HIV infections by demonstrating that nef-
derived miRNAs are produced in HIV-1-infected cells. The
results presented here show that nef short hairpin RNAs
(shRNAs) corresponding to the nef  miRNAs efficiently
block RNA stability or mRNA translation, perhaps an
indication that HIV-1 regulates its own replication by
using nef miRNAs.
Results and Discussion
Identification of a candidate of miRNAs in HIV-1-infected 
cells
Very recently, the Epstein-Barr virus (EBV)-encoded miR-
NAs were identified. Thus, during the preliminary stages
of this study, our curiosity was fixed on the need to find
out if indeed there was any relationship between nef miR-
NAs and HIV-1-infected cells. To achieve this purpose, we
extracted total RNA from HIV-1 IIIB strain persistently
infected MT-4 T cells and northern blot analysis was per-
formed using eight probes against the nef coding region,
as shown in Figure 1A. Analyses using several anti-sense
probes, small RNA molecules approximately ~25-nt in
size were detected as well as HIV-1 major transcripts, 9.1,
4.3 and 1.8 kb bands (Fig. 1B). Similar results were
obtained with total RNA from HIV-1 SF2 strain infected
MT-4 T cells (data not shown). RNA samples treated with
a mixture of the single stranded specific RNases A and T1
also generated ~25-nt RNAs that hybridized in northern
blots with the sense probes against the same nef region.
However HIV-1 major transcripts were not detected (data
not shown), indicating that the structure of the small RNA
molecules could be double-stranded RNAs (miRNAs).
Some variability was observed when the quantity of the
miRNAs was compared with the total of the major tran-
scripts. A maximum of 3.2% of miRNAs was detected by
using #367 probe when compared with total HIV-1 tran-
scripts, and the minimum of 0.3% was detected by using
probe# 90 (Fig. 1B).
To randomly clone the nef miRNA, ~25-nt RNAs were gel
purified, cloned and sequenced. The sequences from the
nef miRNA clones were 5'-acugaccuuuggauggugcuucaa-3'
or similar ones, corresponded to the nucleotides approxi-
mately 420 to 443 conserved region of nef (miR-N367).
The most notable feature of this analysis is that it has
proven beyond reasonable doubts that nef-derived miR-
NAs are produced in HIV-1 infected cells.
Inhibition of Nef by plasmids-encoding siRNA/miRNA
To examine inhibition of nef  expression by the nef
miRNA, we constructed eight shRNAs homologous to the
native miRNA or probes used in Figure 1A[21]. Although
it has been reported that three to four mutations in the
sense strand derived from miRNA could have the poten-
tial to control unmutated 21-nt stem loop [22], we inves-
tigated whether the native shRNA-expressing plasmid can
effectively reduce nef gene expression or not (Fig. 1C and
1D). We used egfp or luc gene (pH1/siegfp or luc) as aRetrovirology 2004, 1:44 http://www.retrovirology.com/content/1/1/44
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Detection of HIV-1 nef miRNAs and inhibition of Nef expression by nef RNAs Figure 1
Detection of HIV-1 nef miRNAs and inhibition of Nef expression by nef RNAs. (A) Schematic representation of HIV-1 nef in its 
genome and synthetic DNA probes (#) used in this study. (B) Total RNAs were extracted from MT-4 T cells persistently 
infected with HIV-1 IIIB, separated on a 15% polyacrylamide-7 M urea gel, and subjected to northern blot analysis. The approx-
imate sizes of the three classes of HIV-1 transcripts and small RNAs are indicated on the right. The loading control was rRNA 
stained with ethidium bromide. Relative expression (%) of nef small RNAs to the three classes of HIV-1 transcripts is at the 
bottom of figure. (C) Schematic representation of effector plasmids (E) H1 promoter-driven shRNA expression plasmids. 
Reporter (R) Nef-EGFP expression plasmid (pYM2.2) is also shown. (D) Inhibition by sinefs in pH1 plamids of Nef-EGFP 
expression. Either sinef, siluc or siegfp in each plasmid was transfected into Jurkat T cells in the presence of either pYM2.2 or 
control pEGFP-N1. At 36 h after transfection EGFP-positive cells were counted by flow cytometry. Data represent the relative 
activity of EGFP-positive cells where the percentage of positive cells in the sample transfected with pYM2.2 or pEGFP-N1 plus 
pcDNA3.1 or si(-) in pH1 plasmid was scored as 100%. Data are averages of three independent experiments + SD. Bars, SD. 
(E) Immunoblot analysis showing inhibition of YM2.2 expression by different nef shRNAs. Jurakat T cells were transfected with 
pYM2.2 and pH1/sinefs or siluc plasmid, cellular lysates were prepared 48 h after transfection, and immunoblotted with rabbit 
serum against Nef (upper panel) and anti-β-actin antibody (lower panel). The β-actin expression shows equal loading of all 
samples.Retrovirology 2004, 1:44 http://www.retrovirology.com/content/1/1/44
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positive or negative control. All the shRNA-expressing
plasmids including the controls were co-transfected into
Jurkat T cells with pYM2.2 and cell fluorescence resulting
from the expression of EGFP reporter gene was quantified
by flow cytometry. The sinef176, 190, 367/miR-N367 and
control siegfp all showed efficient reduction, but the sinef
007, 084, 299, 468 and 580 constructs gave only modest
reductions, and no suppression was observed with si(-)
and luc (Fig. 1D and Table 1). Immunoblot analysis using
anti-Nef rabbit serum also confirmed the inhibition of
Nef-EGFP expression by sinef 176, 190 and 367/miR-
N367 (Fig. 1E).
Inhibition of Nef expression by STYLE vector-encoding nef 
siRNA/miR-N367
To assess the effects of nef  miR-N367 in vivo, we con-
structed a prototype foamy virus (PFV)-based live vector.
The PFV vector expressed HIV-1 SF2 nef gene as a reporter
and the STYLE vector expressed shRNA as effectors. The
full-length nef gene was inserted into the bel-2 portion of
a PFV clone (22) in frame to obtain pPFV/nef (Fig. 2A).
The pPFV/nef was transfected into BHK cells and treated
with the histone deacetylase inhibitor, trichostatin A (TA)
[23]. The viral supernatant, which contained approxi-
mately 5 × 106 infectious units (IFU), was collected at 72
h after transfection. For preparation of the STYLE vectors
to deliver the shRNAs, the env gene portion of pSKY3.0
was replaced with the shRNA expression cassette under
the control of the H1 promoter. The pSTYLE was pro-
duced (Fig. 2A), and transfected into the FFV envelope-
expressing packaging cells, CRFK sugi clone # 6, in the
presence of TA. The transfected CRFKsugi clone #6 had
99% FFV Env positive cells when analyzed by flow cytom-
etry. The viral supernatant with a titer of ca. 1 × 105 IFU
was collected at 72 h post-transfection.
The expression of viral mRNAs and integrated DNAs from
either the PFV/nef or STYLE vectors was confirmed by
infection of Jurkat T cells. The mRNAs and genomic DNA
were extracted from the infected cells at 2 weeks post-
infection. The PFV/nef-expressed gag and nef mRNAs and
the STYLE-expressed gag  mRNA were detected after
amplification of these regions using reverse transcription
(RT)-PCR. The integration of the DNAs into the genome
of Jurkat T cells was also confirmed by PCR of the LTR, gag
and/or nef regions (Fig. 2B). The control SKY3.0 and PFV-
infected cells were both negative for nef mRNA and inte-
grated DNA (Fig. 2B). The integrated DNA was also
detected by southern blot analysis with genomic DNA of
either PFV/nef or STYLE-infected cells (data not shown).
Expression of shRNAs (~22-nt) was also confirmed in
STYLE-infected cells by northern blot analysis (data not
shown). Expression of Nef protein in PFV/nef-infected
cells was also detected with specific rabbit anti-Nef serum
in immunoblots (data not shown).
To evaluate whether the STYLE encoding siRNA could
inhibit the expression of the nef gene in cultured human T
Table 1: Relation between AIDS clinical courses and nef dsRNA or siRNA/miRNA in suppression of nef gene expression
Nef inhibitor Nef expressed by: Target region Clinical courses
Nef-EGFP HIV-1 IIIB PFV/nef
dsRNA* Human
SF2 ++ † ++ ND‡ Full-length (including miR-N367) ND
1-3-3 ++ - ND U3 deleted Rapid progressor, Died within 3 years
4-2-1 ND + ND U3 region (including miR-N367) Rapid progressor, Died within 3 years
15-2-2 ++ +++ ND U3 region (including miR-N367) Non progressor with low plasma viremia
16-1-1 ND + ND U3 deleted Non progressor with low plasma viremia
jw95-1 ND + ND U3 region (including miR-N367) Non progressor with undetectable viremia
siRNA 15-2-2 model mouse
dsnef + + + Full-length ND
sinef007 + ND ND Upstream of U3 region ND
sinef084 + ND ND Upstream of U3 region ND
sinef176 +++ +++ ++ Upstream of U3 region§ ND
sinef190 +++ +++ +++ Upstream of U3 region ND
sinef299 + ND ND U3 region (aa 83–135) ND
sinef367/miR-N367 ++ +++ ++ U3 region No weight loss
sinef468 + ND ND U3 region ND
sinef580 + ND ND U3 region ND
*dsRNA to LTNPs' nef has been described (Yamamoto et al., 2002).
† -, negative; +, 0 to 50 % inhibition; ++, 50 to 75% inhibition; +++, 75 to 100 % inhibition.
‡ ND, not done.Retrovirology 2004, 1:44 http://www.retrovirology.com/content/1/1/44
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Inhibition of nef expression in human T cells by nef siRNAs Figure 2
Inhibition of nef expression in human T cells by nef siRNAs. (A) Schematic representation of shRNA-expressing STYLE vector 
(E) and HIV-1 SF2 nef gene expressing pPFV/nef vector (R). The helper plasmid, pFFenv expresses FFV envelope protein under 
the control of CMV promoter. (B) Detection of expression of nef mRNA and integration of vectors. STYLE, SKY3.0, PFV/nef, 
PFV or mock was used to infect Jurkat T cells and the infected cells were cultured for 2 weeks. After 2 weeks, gag and nef 
mRNA expression was measured by RT-PCR. Genomic DNA of LTR, gag and nef of STYLE or PFV/nef were also detected by 
PCR. β-actin was used as a control. (C) Inhibition of Nef-EGFP expression by nef siRNA-expressing STYLE in Jurkat T cells. 
The pYM2.2 was transfected into each of the STYLE or mock-infected Jurkat T cells and EGFP-expressing cells were counted 
by flow cytometry at 48 h after transfection. Data represent the relative activity of EGFP-positive cells, where the percentage 
of positive cells in the sample transfected with pYM2.2 upon the STYLE-si(-) infected cells was scored as 100%. (D) Inhibition 
of HIV-1 transcription and replication by nef STYLE-367. HIV-1 IIIB persistently infected MT-4 T cells were transfected with 
the pLTRSF2 reporter and β-gal expressing control pCMVβ plasmids at 72 h after infection with STYLE. At 48 h post-transfec-
tion, Luc activity was measured and normalized as Luc values (Luc/β-gal). Absolute levels of Luc activity in the samples of 
pLTRSF2 plus SRYLE-si(-) were 16,311 + 1,253 or 783 + 87 light units for STYLE-367/miR-N367 transfectants. Data represent 
the relative Luc activities where the percentage of positive cells in the samples infected with the STYLE-si(-) was scored as 
100%. After 48 h, p24 antigen was also measured in the cell culture supernatant of STYLE-infected Jurkat T cells. Data are aver-
ages of three independent experiments + SD. Bars, SD. (E) Inhibition of nef expression by nef siRNA in Jurkat T cells. Cells 
were infected with PFV/nef 48 h after infection with the STYLE and then subjected to semi-quantitative RT-PCR analysis. Data 
represent the relative expression of mRNA, where the percentage of positive cells in the sample of mock-infected cells (E: 
Mock) relative to the PFV/nef (R: PFV/nef) infected cells was scored as 100%. Data averages were derived from three inde-
pendent experiments + SD. Bars, SD.Retrovirology 2004, 1:44 http://www.retrovirology.com/content/1/1/44
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cells, pYM2.2 was transfected into each of the STYLE-
infected Jurkat T cells (m.o.i. = ca. 0.1). The most efficient
sinef176, 190 and 367/miR-N367 vectors for reduction in
nef  expression (Fig. 1D and 1E) were selected for this
experiment. The EGFP-positive cells were counted by flow
cytometry at 48 h after transfection. Expression of Nef-
EGFP fusion protein was reduced drastically following
treatment with either the STYLE-176 (74 + 3.2) or 190 (51
+ 4.2) and also reduced with 367/miR-N367 (32 + 2.3%).
Reduction was insignificant with either the STYLE-si(-) (0
+ 0.7) or STYLE-luc (7 + 0.9%) controls (Fig. 2C).
The in vitro inhibitory effects of STYLE encoding nef siRNA
on HIV-1-infected cells were evaluated in Luc assays and
using MT-4 T cells persistently infected with HIV-1 IIIB.
Cultivation of the STYLE infected cells for 72 h followed
by transfection with the pLTRSF2 and culture for another
48 h showed that STYLE-176, 190 and 367/miR-N367 all
significantly (p < 0.005) suppressed Luc activity when
compared to controls (Fig. 2D). HIV-1 p24 Gag was also
significantly inhibited in the culture supernatant by infec-
tion with STYLE-176, 190 and 367/miR-N367 when com-
pared to controls (p < 0.001) (Fig. 2D). These data
suggested that shRNA/miR-N367 could inhibit HIV-1
transcription and replication in intact HIV-1-infected
human T cells.
Jurkat T cells that had been transduced with nef shRNA for
48 h were infected with the PFV/nef. Semi-quantitative
RT-PCR analysis revealed that while treatment with
STYLE-190 dramatically reduced the expression of both
nef and gag mRNAs of the PFV/nef, the expression of nef
mRNA was also drastically suppressed by STYLE-176 and
367/miR-N367 (Fig. 2E). However the STYLE-si(-) and luc
controls showed ~10% suppression of nef and ~20% sup-
pression of gag mRNAs (Fig. 2E), which was probably a
result of interference following super-infection.
Nonetheless, both nef transcription and PFV/nef replica-
tion were substantially inhibited by STYLE-176, 190 and
367/miR-N367.
Inhibition of Nef expression by siRNA/miR-N367 in mice
Since different host gene products are required for siRNA-
mediated RNAi and miRNA-mediated translational
repression with let-7 and lin-4 in C. elegans, the two RNAs
may not have the same functions in vivo [24]. To test this
point, we investigated the efficacy of miR-N367 using
STYLE-367 in mammalian tissues. The study mice were
group 1 = PFV/nef-infected (n = 6); group 2 = PFV/nef and
control STYLE-luc infected (n = 6); group 3 = PFV/nef and
STYLE-367-infected (n = 8); and group 4 = STYLE-367-
infected (n = 6). Identical study groups were used for both
Balb/c and C3H/Hej mouse strains. Nef protein express-
ing lymphocytes were quantified by histochemical analy-
sis using F3 Nef monoclonal antibody (mAb) or anti-Nef
rabbit serum 2 days after PFV/nef infection. Nef protein
was detected by immunofluoresence assay in the subcap-
sular area of the spleens of groups 1 or 2 Balb/c mice, but
not groups 3 or 4 (Fig. 3A and Table 2). No positive cell
staining was observed using normal rabbit serum as a pri-
mary antibody (Fig. 3A). To test the expression of nef,
nested RT-PCR was also done on day 2 to evaluate the
degree of nef mRNA expression in the spleen, liver, adi-
pose tissues and hematopoietic cells in groups 1–4. The
nef mRNA was significantly expressed in liver and hemat-
opoietic cells of Balb/c mice in groups 1 and 2, but not in
the group 3 animals that were STYLE-367 infected (Table
2). Tissues from group 4 did not show any nef bands after
RT-PCR (data not shown).
Because extracellular Nef is internalized into human and
mouse lymphocytes and macrophages [25-27], we exam-
ined putative Nef receptor molecule (Ner) expression with
305 mAb [27] in both mouse and human tissues by histo-
chemical analysis. In mice, 305 mAb positive lym-
phocytes were detected in the subcapsular area of the
spleens by immunofluoresence assay (Fig. 3B) and liver
and hematopoietic cells (Table 2) in groups 1, 2 and 3,
indicating that detection of antigen by 305 mAb was not
altered by Nef expression. In HIV-1 uninfected humans,
the 305 mAb positive cells were detected by immunoper-
oxidase staining in spleen (red pulp), tonsillar follicle
(germinal center), liver (Kupffer cells), salivary gland (ger-
minal center and adipose cells), bronchi (smooth muscle
cells), lung (stroma cells), thyroid gland (colloid), heart
muscle (smooth muscle cells), prostate gland (smooth
muscle cells), colon mucosa (intestinal absorptive and
muscle cells), testis (basement membrane of tubuli sem-
iniferi), adrenal gland (adipose cells), and brain (cere-
brum cortex and cortical cells) (Fig. 3B and Table 2).
Since Nef suppressed PPARγ expression and reduced fatty
acid levels in vitro [29-32], we monitored the expression of
PPARγ  mRNA and body weights of mice. Significant
PPARγ mRNA expression in intestinal adipose tissue of
group 3, but not group 1 and 2, was detected on day 2
(Table 2). All Balb/c mice in group 1 showed sedation and
a drastic loss of weight from days 1 to 3 (day 1, p = 0.003;
day 2, p = 0.021; day 3, p = 0.032 relative to mice in group
3) (Fig. 3C). Similar results were obtained in group 2 (Fig.
3C). However, group 3 mice infected with STYLE-367 did
not appear to be sedated and had no drastic loss of weight
(Fig. 3C). The group 4 animals, which were not infected
with the PFV/nef but treated with STYLE-367, had no
changes in either behavior or weight (Fig. 3C). In longitu-
dinal examinations done during the post-infection
period, the animals in groups 1 and 2 had recovered the
lost weight (Fig. 3D). Similar results were obtained in
group 2 from day 1 to 5 (day 1, p = 0.037; day 3, p = 0.044;
day 5, p = 0.048 relative to mice in group 3) in the C3H/Retrovirology 2004, 1:44 http://www.retrovirology.com/content/1/1/44
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In vivo effects of miR-N367 Figure 3
In vivo effects of miR-N367. (A) Distribution of Nef positive staining cells in the subcapsular area of groups 2 or 3 mouse 
spleens at 2 days after infection with PFV/nef. Anti-Nef rabbit serum or normal rabbit serum was used as a primary antibody. 
(B) Immunofluorescence for 305 mAb positive staining cells in the subcapsular area of groups 2 or 3 mouse spleens at 2 days 
after infection with PFV/nef and immunoperoxidase staining by 305 mAb in cells of interfollicular area of HIV-1 uninfected 
human spleen and tonsillar follicle. (C) Short term body weights of PFV/nef-infected Balb/c mice. The body weights of the PFV/
nef-infected mice (group 1, n = 6, solid circle), the PFV/nef-infected followed by the STYLE-luc-infected mice (group 2, n = 6, 
solid triangle), the PFV/nef-infected followed by the STYLE-367-infected mice (group 3, n = 8, open triangle) and the STYLE-
367-infected mice (group 4, n = 6, open circles) were measured from days 0 to 5. (D) Long term body weights of PFV/nef-
infected C3H/Hej mice. Treatment of each group and numbers of mice were same as (C). Bars, SD. *; p < 0.05, **; p < 0.01 
(relative to group 3). (E) Immunoperoxidase staining by 305 mAb and anti-Nef rabbit serum in cells of mouse or human adi-
pose tissue. Arrows show positively stained areas. Magnification, X 20 (A and B); X 20 and X 200 (E).Retrovirology 2004, 1:44 http://www.retrovirology.com/content/1/1/44
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Hej mouse groups (Fig. 3D). To assess the above in vivo
results, expression of nef mRNA was examined in adipose
tissues (Table 2). As shown in Table 2, although mRNAs
of nef and gag were not detected in mouse adipose tissues,
305 mAb and anti-Nef rabbit serum positive staining cells
were detected in mouse group 1 and 2 adipose tissues
(Fig. 3E and Table 2). Considering that the 305 mAb pos-
itive staining adipocytes appeared in mouse as well as
human tissues (Fig. 3E and Table 2), these data suggest
that the interaction between 305 and soluble Nef detected
in adipose tissues may be responsible for the weight loss
observed in mice.
In this study, whereas siRNA has been reported to inhibit
hepatitis B virus replication in vivo (33–34), our results
show that nef-derived miRNAs are produced in HIV-1
infected cells, and support the possibility that miRNA and
siRNA may be functionally identical, at least in a retro-
transposon such as HIV. Recent studies have revealed that
miRNAs and siRNAs could block mRNA expression by
similar mechanisms [9] and that siRNAs could function as
miRNAs [35] and EBV-encoded miRNAs were found [36].
Our results reported here are consistent with these previ-
ous observations and are suggestive of the fact that nef
miR-N367 could regulate nef expression even in vivo. In
our unpublished data, HIV-1 LTR promoter activity was
inhibited by miR-N367 (nt number 379 to 449 of SF2 nef,
71-nt) expression, of which activity was dependent on
negative responsive element (NRE) of U3 region (our
unpublished data). Although no mismatch shRNA against
region #367 was active, the miR-N367 from HIV-1
genome may have some mismatches and effectively
inhibit HIV-1 transcription. Further the effects of siRNAs
of Tc1, in particular those to the terminal inverted repeats
derived from read-through transcription of entire trans-
posable elements, were presented for silencing
transposase gene expression by RNAi machinery in germ
lines of C. elegans, [37]. Taken together, it could be
implied from these and our other results that miRNAs
produced in HIV-1-infected cells can efficiently block not
Table 2: Histochemical detection and RT-PCR amplification of Nef from human and mouse tissues
Tissues Histochemistry* RT-PCR†
F3 Anti-Nef rabbit 
serum
305 nef gag PPARγ
Human (HIV-1 uninfected)
Spleen -§ -+-- ‡ ND
Tonsillar follicle - - + - - ND
Liver - - + - - ND
Adipose tissue (Salivary gland) - - + - - +
Bone marrow - - + - - ND
Bronchi - - + - - ND
Thyroid gland - - + - - ND
Heart muscle - - + - - ND
Prostate gland - - + - - ND
Testis - - + - - ND
Colon mucosa - - + - - ND
Lung - - + - - ND
Adrenal gland - - + - - ND
Brain (Cerebrum cortex) - - + - - ND
Mouse Group 1 and 2
S p l e e n +++++ N D
Liver ND ND + + + ND
Hematopoietic cells ND ND + + + ND
Adipose tissue (Intestine) + + + - - -
Mouse Group 3
Spleen - - + ± ± ND
Liver ND ND + - - ND
Hematopoietic cells ND ND + - - ND
Adipose tissue (Intestine) - - + - - +
*Histological analysis was performed with human or each group of mouse tissues by using F3 anti-Nef mAb, anti-Nef rabbit serum or 305 mAb as a 
primary antibody. For secondary antibody, FITC or peroxidase-conjugated antibody was used.
†HIV-1 nef, PFV gag (‡HIV-1 gag for human tissues), and PPARγ mRNA expression were detected by RT-PCR with mRNA from human or each 
group of mouse tissues.
§+, positive; -, negative; ND, not done.Retrovirology 2004, 1:44 http://www.retrovirology.com/content/1/1/44
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only Nef function but also HIV-1 replication through
RNAi, which renders persistently low pathogenic infec-
tion latent as observed in an LTNP of 15-2-2 (see Table 1).
It is equally important that although the weight loss
reported here occurred only temporarily in vivo, however
the inserted nef gene in the foamy retrotransposon may
represent miRNAs which could inhibit nef mRNA expres-
sion by presumably an identical mechanism to that
observed of siRNAs. Thus, RNAi might serve as a new
sequence-specific therapeutic arsenal in AIDS prevention
and possibly treatment.
Overall, our results indicate that nef shRNA transduced
into T cell line inhibited HIV-1 transcription. Further, nef
miRNAs could be produced from infected T cells and can
block the trans-activity of Nef as well as HIV-1 replication
on its own via the cis-action of nef. These functions of nef
via RNAi pathways may allow persistently low pathogenic
or latent infection as observed in HIV-infected non-pro-
gressors. Cumulatively, these data suggest that Nef may be
involved in both viral replication and the disease progres-
sion, the findings, which may facilitate new strategies for
HIV control in vivo.
Materials and Methods
Patient details
Patient selection is showed in Table 1. These SF2 (HIV-1
subtype B prototype) was included as a control nef
sequence, because of the inclusion of viruses, which were
also subtype B. The SF2 contained full-length nef reading
frame as indicated in Table 1. Patients 1-3-3, 4-2-1 (Table
1) are rapid progressors infected with HIV-1. These
patients were infected in 1984–1985 and died within 3
years of primary infection with >1 × 106 viral copies and
CD4+ T cell count of 75 and 110/ml blood. Patients 15-2-
2 and 16-1-1 (Table 1) are slow progressors, who were
infected in 1984 and have survived HIV-1 infection with
high and stable CD4+ T cell counts (690 and 760/ml
blood) with low (<5000 copies) plasma viremia. All these
patients acquired virus through homosexual sex. JW95-1
(Table 1) is a boy who was infected from his mother via
breast feeding. The child was infected in 1983 and has sur-
vived disease free with high CD4+ T cell count (890/ml
blood) with undetectable viremia. Human samples were
obtained from a donor after informed consent.
Cells and viruses
HeLa and BHK cells were grown in Dulbecco's modified
Eagle Medium (DMEM) (GIBCO, Grand Island, NY) sup-
plemented with 10% heat-inactivated fetal bovine serum
(FBS) and antibiotics. CRFK cells were grown in Iscove's
Modified Dulbecco's Medium (IMDM) (GIBCO) with
10% FBS and antibiotics. Jurkat T cells and MT-4 T cells
persistently infected with HIV-1 IIIB strain were cultured
in RPMI-1640 medium (GIBCO) supplemented with
10% FBS and antibiotics. The packaging cells (CRFKsugi)
were made by transfecting CRFK cells with 10 µg of the
pFFenv with Lipofectin Reagent (Invitrogen) and selecting
transformants after culture for 14 days with 25 µg/ml of
hygromycine B (Invitrogen). After 14 days, FFV Env pro-
tein expression was measured by flow cytometry and
immunoblot analyses with FFV-infected cat B serum [34].
The pPFV/nef (10 µg) was transfected into BHK cells and
pSTYLE/si (10 µg) was transfected into CRFKsugi cells
with Lipofectin Reagent. The transfected cells were cul-
tured for 72 hr, and the viral supernatant was collected
and filtered through a 0.45 µm pore size Millex-GP filter
(Millipore, Bedford, MA). Vector stocks were stored at -
70°C prior to use. Viral titers were determined as
described previously [21]. Cells were infected with PFV/
nef and/or SKY/si at an m.o.i. of ca. 0.1 in the presence of
4 µg/ml of polybrene and infected cells were cultured at a
density of 1 × 106 cells per ml for 3 days.
The details of plasmid constructs and the primer
sequences used in cloning strategies are shown in supple-
mentary file (see Additional file: 1).
Flow cytometric analysis
Flow cytometry was performed with a FACS Calibur (Bec-
ton Dickson, San Jose, CA) as described previously [17].
Luc assay and Immunoblotting
Firefly Luc assay was performed using the Luciferase Assay
System (Promega) as described previously [17]. Immuno-
blotting was performed essentially as described previously
by Otake et al. [28].
P24 ELISA
The concentration of p24 supernatant was determined by
an antigen capture assay (Beckman Coulter, Fullerton,
CA) according to the manufacturer's instructions.
Confocal laser microscopy analysis
Confocal laser microscopy analysis was performed as
described previously [28].
Northern blot analysis
Total RNAs were extracted from HIV-1 IIIB or SF2 persist-
ently infected or uninfected MT-4 T cells using TRIzol rea-
gent (Invitrogen). Approximately 40 µg of total RNA was
treated with RNase A and T1 (Sigma, St. Louis, MO) as
described previously [17], subjected to electrophoresis on
a 15% polyacrylamide-7 M urea gel and electroblotted to
HybondN+ (Pharmacia, Uppsala, Sweden) for 4 hr at 400
mA. RNAs were immobilized by UV crosslinking and bak-
ing for 1 hr at 80°C. Hybridization was done with an ECL
direct Kit (Pharmacia). Synthetic DNA probes were
labeled with horseradish peroxidase. The sequence for
synthetic sense DNA probes for northern blot analysis areRetrovirology 2004, 1:44 http://www.retrovirology.com/content/1/1/44
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as follows: #007 (5'-gcgtcgacggcaagtggtcaaaacgta-3');
#084 (5'-gcgtcgacgccagcagcagatggggtg-3'); #176 (5'-gcgtc-
gacgtgcctggctagaagcaca-3'); #190 (5'-gcgtcgacgcacaagag-
gaggaga-3'); #299 (5'-gcgtcgacgactggaagggctaatttg-3');
#367 (5'-gctcgacggctacttccctgattggc-3'); #468 (5'-gcgtc-
gacggtagaagaggccaatgaa-3'); #580 (5'-gcgtcgacgcatttcatca-
catggccc-3'). RNAs were cloned by 5'RACE System
(Invitrogen, CA., USA) with a slight modification in that
primers were used that were the same as the synthetic
DNA probes as described above that are abbreviated as
#primer. In brief, gel purified small RNAs were annealed
with #primer and first strand cDNA was synthesized with
SuperScript II RT (Invitrogen, CA., USA). Afrer RNase H
and T1 treatment, a homopolymeric tail was added to the
3'-end of the cDNA using terminal deoxynucleotidyl
transferase and dCTP. After ethanol precipitation, PCR
amplification was done with abridged anchor primer and
#primer. Then the PCR products were obtained using
abridged universal amplification primer and #primer. The
PCR fragments were digested with SalI and cloned into
SalI site of pBluescript SK(-), followed by sequence analy-
sis. The secondary structures of RNAs were predicted by
GENETYX-MAC program (Software Development Co.
Ltd, Tokyo, Japan).
Semi-quantitative RT-PCR analysis
Semi-quantitative RT-PCR analysis was performed using
the ThermoScript RT-PCR System (Invitrogen, CA., USA)
according to the manufacturer's protocol with the follow-
ing primers: III (5'-atcatgggccaaagagaattc-3') and IV (5'-
aaatttcactcaatcgagcc-3') for FFV LTR, VI (5'-aggacctgaaag-
gcatg-3') and VII (5'-ttgttgagatcgtcccg-3') for FFV gag, VIII
(5'-tgtggtggaatgccactag-3') and IX (5'-attgtcatggaattttgta-
3') for PFV LTR, XI (5'-tcttacagaccagtaacaa-3') and XII (5'-
gtcaatcattacatctgca-3') for PFV gag, XIII (5'-aactactagtaccct-
tcagg-3') and XIV (5'-aaaactcttgctttatggcc-3') for HIV-1 gag,
XV (5'-atgggtggcaagtcaaaacg-3') and XVI (5'-tcagcagtctttg-
tagtactccg-3') for HIV-1 nef, XVII (5'-gttatgggtgaaactctggga-
gat-3') and XVIII (5'-atgttcctgaacataatcgtc-3') for PPARγ,
XIX (5'-gacaacggctccggcatgtgcaaag-3') and XX (5'-ttcacggtt-
ggccttagggttcag-3') for β-actin, respectively. The nested
PCR followed RT reaction was performed as described
previously [34]. PCR products were quantified with the
NIH image program. Relative mRNA expression was cal-
culated as percentage expression using the following for-
mula: integrating number of nef or gag bands/integrating
number of β-actin X 100.
In vivo studies and tissue analyses
Balb/c and C3H/Hej mice were raised under specific path-
ogen-free (SPF) conditions. Mice were infected with 1 ml
of 105 IFU of PFV/nef and STYLE-367 by intravenous (i.v.)
injection. RT-PCR analyses were performed 2 days after
infection. For histological analysis, cryostat sections were
prepared from both human and mouse tissues. The fixed
sections were rinsed with PBS and incubated with 5% BSA
for at least 1 hr to inhibit nonspecific binding of antibod-
ies. Sections were incubated overnight at 4°C with anti-
Nef rabbit serum, F3 or 305 mAb, and incubated with
peroxidase or FITC conjugated secondary antibodies. The
washed sections were incubated in 0.03% 3,3'diami-
nobenzidine (Sigma) solution in 0.05 M Tris buffer with
0.01% H2O2 for development of peroxidase activity. After
counterstaining with hematoxylin or methylgreen, the
sections were dehydrated and mounted.
Statistical methods
Data were analysed using a one-way ANOVA analysis with
a post-hoc Fisher's test. P values of 0.05 or more were
determined for that of cut off.
List of abbreviations used




shRNA short hairpin RNA
AIDS acquired immunodeficiency syndrome
RNAi RNA interference
siRNA small interfering RNA
LTR long terminal repeat
SIV simian immunodeficiency virus
PBMCs peripheral blood mononuclear cells;
EBV Epstein-Barr virus;
EGFP enhanced green fluorescence protein
PFV prototype foamy virus
TA trichostatin
A IFU infectious units
FFV feline foamy virus
RT reverse transcription
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Ab monoclonal antibody;
Ner Nef receptor molecule;
NRE negative responsive element.
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